ORY Oryzon Genomics S.A.

2.687USD2.450 EUR · BME+5.51%Mkt Cap: 220.23M USDP/E: —

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hemato…

Institutional holders7 on file

Key Statistics

Company
Market Cap220.23M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit10.65M USD
Net Income (TTM)-2.61M USD
Revenue/Share0.14 USD
Last Price2.687 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees46
CountryES
SectorHealthcare
IndustryBiotechnology
ISINES0167733015
Valuation
P/E (Trailing)—
P/E (Forward)46.39
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.63
EPS (TTM)-0.03 USD
EPS (Forward)0.05 USD
52W Range
2.44617% of range3.905
52W High3.905 USD
52W Low2.446 USD
Profitability
Gross Margin97.75%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-15.76%
ROE-2.21%
ROA-1.80%
ROIC-2.94%
ROCE-4.43%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.36M USD
CapEx (TTM)11.04M USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.06
Current Ratio—
Quick Ratio—
Book Value/Sh1.52 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.884 USD
Upside (mean)+230.6%
Target Range4.607 USD – 13.16 USD
4.607+230.6% to mean13.16
# Analysts2
Ownership
Shares Out.81.96M
Float64.94M
Insiders20.97%
Institutions1.87%
Technical
SMA 502.840 (-5.4%)
SMA 2003.115 (-13.7%)
Beta0.42
S&P 52W Chg12.00%
Avg Vol (30d)291.50K
Avg Vol (10d)405.48K
Technical Indicators
RSI (14)48.9
MACD-0.0584
MACD Signal-0.0659
MACD Hist.+0.0074
BB Upper2.820 USD
BB Middle2.654 USD
BB Lower2.487 USD
BB Width12.53%
ATR (14)0.1205 USD
Vol Ratio (20d)3.19x

About Oryzon Genomics (BME: ORY)

›

Oryzon Genomics (BME: ORY) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 46 employees.

The shares were at 2.450 EUR on 19 November 2026, down 19.1% over 52 weeks. Its 52-week range is 2.230 EUR to 3.560 EUR: the price is 31.2% below the high and 9.9% above the low.

Its market capitalisation is 200.80M EUR.

Oryzon Genomics reports return on equity of -2.2% and an operating margin of 0.0%.

Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 8.100 EUR is 230.6% above the current price. The next earnings report is expected on 11 February 2027.